scholarly journals Breast cancer as a systemic disease: a view of metastasis

2013 ◽  
Vol 274 (2) ◽  
pp. 113-126 ◽  
Author(s):  
A. J. Redig ◽  
S. S. McAllister
Keyword(s):  
Breast Cancer ◽  
Systemic Disease

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

2021 ◽  
pp. 41-44
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Histological Grade ◽  
Systemic Disease ◽  
Lymph Node Involvement ◽  
Hormone Receptor Status ◽  
Major Health Problem ◽  
Receptor Status ◽  
Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

scholarly journals CUTANEOUS METASTASES UNVEILING BREST CANCER – THERAPEUTIC AND DIAGNOSTIC CONSIDERATIONS

2020 ◽  
Vol 7 (1) ◽  
pp. 164-168
Author(s):  
Florica Sandru ◽  
Mihai Cristian Dumitrascu ◽  
Aida Petca ◽  
Raluca Gabriela Miulescu ◽  
Tiberiu Tebeica ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Systemic Disease ◽  
Lymph Node Biopsy ◽  
The Body ◽  
Cervical Region ◽  
Cutaneous Lesions ◽  
Dermatology Department ◽  
Efficient Treatment ◽  
Surgery Department

Metastatic cutaneous lesions are seen more commonly in breast cancer than in any other malignancy in women. Secondary breast cancer happens when cancer cells spread from the breast to other parts of the body. Sometimes breast cancer cells can spread to the skin. This can happen through the blood or lymphatic system. The presence of skin metastases signifies widespread systemic disease and a poor prognosis. The chest wall, the abdomen, the back, and the upper extremities are common sites.We present the case of a 69-year-old woman presented to our Surgery Department in June 2019, after appearing in the Dermatology Department a week ago, for the appearance of multiple subcutaneous painless, hardened, skin-colored nodules spread to the cervical region, anterior chest walls and upper limbs. Anatomopathological examination of the skin biopsy, performed on the anterior face of the left arm, showed dermal fragment with neoplastic, suggestive for lobular breast carcinoma (stage IV). The patient was referred to the oncological surgery department where our patient underwent a left total mastectomy and sentinel lymph node biopsy. The technique of mastectomy was the Madden technique. The surgery has no healing character, being more a necessity intervention that seeks to avoid the complications of the local evolution of the disease, such as ulceration, hemorrhage or suppuration, the possibility of applying the other forms of treatment (radiotherapy and / or polychemotherapy), elimination of a source of permanent metastatic sowing thus leading to more efficient treatment.

Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (Korean Radiation Oncology Group 1612).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e14008-e14008
Author(s):  
In Ah Kim ◽  
Jae Sik Kim ◽  
Kyubo Kim ◽  
Wonguen Jung ◽  
Kyung Hwan Shin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Stereotactic Radiosurgery ◽  
Molecular Subtypes ◽  
Molecular Subtype ◽  
Systemic Disease ◽  
Subsequent Development ◽  
High Dose ◽  
Time Interval

e14008 Background: We analyzed the treatment outcome of breast cancer patients with brain metastases (BM) in Korea to identify the prognostic factors and the role of whole brain radiation therapy (WBRT). Methods: Seven hundred thirty patients of breast cancer with BM treated at 17 institutions in Korea from 2000 to 2014 were analyzed. The median follow-up duration was 12 months. The analysis consisted of three cohorts: in cohort A, a total of 730 patients were included; in cohort B, 538 patients with available follow-up imaging after initial brain-directed treatment; and in cohort C, 54 patients receiving salvage WBRT due to recurrent BM after initial Stereotactic radiosurgery or WBRT. Overall survival (OS) was calculated from BM diagnosis in cohort A or from the last day of salvage WBRT in cohort C. Results: Median OS of cohort A was 15 months. In multivariate analysis, histologic grade 3, extracranial metastasis, number of BM > 4, hormone receptor (HR) or HER2 negativity, and shorter time interval to diagnosis of BM were associated with inferior OS. Among 538 patients in cohort B, 201 showed subsequent development of new BM at a median of 11 months after stereotactic radiosurgery or WBRT for the management of initial BM (at 1 year, HR+/HER2- 51.9%, HER2+ 44.0%, and TNBC 69.6%, respectively; p = 0.008). Upfront WBRT reduced subsequent development of new BM, which showed the significant difference among molecular subtypes (HR+/HER2-, 42% reduction at 1 year, p < 0.001; HER2+, 18.5%, p = 0.004; TNBC, 16.9%, p = 0.071). Multivariate analysis showed that shorter time interval to BM, TNBC subtype, extracranial systemic disease, number of BM > 4, and involvement of both tentoria increased subsequent development of new BM. Anti-HER2 therapy for HER2+ patients and upfront WBRT significantly reduced risk of new BM. In cohort C, upfront WBRT prolonged the salvage WBRT-free duration (median 6.9 vs. 8.7 months, p = 0.058). Median OS was 6.8 months after salvage WBRT. Longer interval to salvage WBRT, controlled primary tumor, high dose of salvage WBRT (BED10 > 37.5 Gy), and systemic treatment after salvage WBRT showed better OS. Uncontrolled extracranial systemic disease and salvage WBRT due to local progression without distant intracranial failure showed worse OS. Conclusions: The rates of new BM showed the significant differences among molecular subtypes. Upfront WBRT decreased subsequent development of new BM and this effect was dependent on the molecular subtype as well. Anti-HER2 therapy for HER2+ patients significantly decreased the subsequent development of new BM. On salvage WBRT setting, the patients having high dose of salvage WBRT, stable extracranial systemic disease and subsequent systemic therapy showed better OS.

Is Breast Cancer Ever Cured? Follow-Up Study of 5623 Breast Cancer Patients

1991 ◽  
Vol 77 (6) ◽  
pp. 465-467 ◽  
Author(s):  
Stefano Ciatto ◽  
Rita Bonardi
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Disease ◽  
Cancer Death ◽  
Breast Cancer Patients ◽  
Death Rates ◽  
Breast Cancer Death ◽  
Long Term Follow Up

The authors evaluated 5623 cases of primary breast cancer followed for 1 to 21 years. Overall and breast cancer death rates were determined and compared to expected rates. Breast cancer patients showed overall and breast cancer death rates significantly higher than expected and which persisted at long-term follow-up. The observed/expected overall death ratios for follow-up periods of 0–5, 6–10, 11–15 or 16–20 years were 3.61, 2.55, 1.60 and 2.11, respectively. Death rates from breast cancer at 5, 10, 15 and 20 years were 20%, 32%, 40% and 48% respectively. The evidence of a persistent excess mortality even after long-term follow-up suggests the hypothesis that breast cancer is a systemic disease when clinically diagnosed. This study provided no evidence of a « clinical » cure for breast cancer patients. Even for N- patients the 5, 10, 15 and 20 year death rates from breast cancer were 12%, 20%, 28% and 38%, respectively. N- breast cancer, which is currently considered as a localized disease cured by surgery in most cases, would be better regarded to as a slow-growing metastatic disease, although « personal » cure may be achieved in many subjects dying of causes other than breast cancer.

scholarly journals A Paternally InheritedBRCA1Mutation Associated with an Unusual Aggressive Clinical Phenotype

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Florentia Fostira ◽  
Nikolaos Tsoukalas ◽  
Irene Konstantopoulou ◽  
Vassilios Georgoulias ◽  
Charalambos Christophyllakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Clinical Phenotype ◽  
Lung Metastases ◽  
Systemic Disease ◽  
Locally Advanced ◽  
Young Females ◽  
High Penetrance ◽  
Triple Negative Tumour ◽  
Exon 11

This report highlights the necessity of genetic testing, at least forBRCA1mutations, of young females diagnosed with triple negative breast cancer, even in the absence of or limited family history. A 34-year-old female with a locally advanced, triple negative tumour, which perforated the skin, is described. At the time of diagnosis, the patient had already multiple lung metastases and although chemotherapy was started immediately, she died with rapid systemic disease progression. The patient was found to carry theBRCA1p.E1060X mutation, which is located on exon 11 of the gene. The high penetrance ofBRCA1gene is not represented in the patient’s family, since the mutation was paternally inherited. It is evident that females belonging to small families, along with paternal inheritance of pathogenicBRCAmutations that predispose for breast cancer, in most cases will probably be genetically tested only after being diagnosed with cancer.

IgG4-related disease of the breast: a systemic disease whose mammary manifestations mimic breast cancer

2015 ◽  
Vol 4 (2) ◽  
pp. 67-72 ◽  
Author(s):  
Takuya Moriya ◽  
Hisashi Hirakawa ◽  
Maki Nagashima ◽  
Mitsuhiko Yasuda ◽  
Izo Kimijima
Keyword(s):  
Breast Cancer ◽  
Systemic Disease ◽  
Related Disease ◽  
Igg4 Related Disease

scholarly journals Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event

2018 ◽  
Vol 11 (2) ◽  
pp. 557-561 ◽  
Author(s):  
Nikolaos Mitsimponas ◽  
Evangelia Klouva ◽  
Dimitrios Tryfonopoulos ◽  
Anastasios Grivas ◽  
Stamatina Demiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Hormone Receptor ◽  
Tendon Rupture ◽  
Medical Literature ◽  
Systemic Disease ◽  
Hormone Receptor Positive ◽  
Antihormonal Treatment ◽  
Antihormonal Therapy ◽  
Positive Breast Cancer

Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case with AI-associated severe tendinopathy has been reported in the medical literature, and there are no recorded cases of AI-associated muscle tendon rapture. We report three cases of postmenopausal women with hormone receptor-positive breast cancer, who experienced tendinopathy or muscle tendon rupture under antihormonal treatment with letrozole. All of the three women were in the adjuvant setting, and the treatment of tendinopathy or tendon rupture consisted of AI discontinuation, initiation of corticosteroids, or surgical treatment. Diagnosis was made via MRI. Furthermore, in our cases, there were no signs of underlying systemic disease, there was no abnormal physical activity preceding the complaints, and there was no use of other drugs beside letrozole. AIs are one of the most commonly used drugs in antihormonal therapy for hormone receptor-positive breast cancer. In every case of a female patient with hormone receptor-positive breast cancer under treatment with AIs and arthralgia, an MRI should be performed in order to exclude the presence of tendinopathy or muscle tendon rupture.

scholarly journals RADI-22. CHARACTERIZING CLINICAL SURVIVAL PATTERNS USING MACHINE LEARNING: AN ANALYSIS OF BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i26-i26
Author(s):  
Ali Alattar ◽  
Rushikesh Joshi ◽  
Brian HIrshman ◽  
Kate Carroll ◽  
Osamu Nagano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Brain Metastasis ◽  
Disease Control ◽  
Stereotactic Radiosurgery ◽  
Cancer Patients ◽  
Systemic Disease ◽  
Breast Cancer Patients ◽  
Clinical Variables ◽  
Gi Cancer

Abstract INTRODUCTION: Increased sophistication in machine-learning algorithms and artificial intelligence have begun to unveil patterns that would be otherwise unappreciated in clinical medicine. Here we applied one such algorithm, Iterative Factorial Analysis of Mixed Data (IFAMD), to better understanding combinations of clinical variables that influence clinical survival of brain metastasis (BM) patients treated with stereotactic radiosurgery (SRS). METHODS: A dataset of 6,326 BM patients was collated from four SRS centers (University of California, San Diego, Katsuta Hospital Mito GammaHouse, Tsukiji Neurological Clinic, and Melanoma Institute of Australia). IFAMD was applied to the analysis of the following clinical variables: age, Karnofsky Performance Status (KPS), cumulative intracranial tumor volume (CITV), total number of metastases, histology (breast, gastrointestinal (GI) cancer, renal cell carcinoma (RCC), melanoma, and lung cancer), systemic disease control, and survival in months. RESULTS: Our machine learning algorithm defined three groups of patients who exhibited differential survival. The group who is most likely to die within 3 months of SRS included patients with lower KPS, poor systemic disease control, higher CITV, higher number of metastasis, and who carried a diagnosis of GI cancer. Patients who are most likely to survive beyond twelve months of SRS fall into two distinct categories. The first consisted of subsets of lung and breast cancer patients with higher KPS, controlled systemic disease, and lower CITV. The second consisted of young breast cancer patients with systemic disease control, independent of KPS, CITV, and the number of metastases. CONCLUSION: Clinical survival after SRS for BM is defined by combinations of known prognostic factors. A prognostic factor critical for survival prognosis in one sub-population of BM patients may bear little relevance in another patient sub-population.

Sign in / Sign up

Export Citation Format

Share Document